Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.
Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.
Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.
While Tacere is weighing the possible expansion of its pipeline, having met this milestone in its flagship drug-development program, the company's management has set its sights on exiting the field through the sale of the company to a bigger player.
Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.